Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy
Articolo
Data di Pubblicazione:
2020
Abstract:
This is a commentary on Agnes Mattsson. et al., Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
Tipologia CRIS:
14.a.1 Articolo su rivista
Keywords:
chronic lymphocytic leukaemia (CLL, fludarabine, cyclophosphamide and rituximab (FCR
Elenco autori:
Mondello, Patrizia; Zelenetz, Andrew D.
Link alla scheda completa:
Pubblicato in: